99 related articles for article (PubMed ID: 23102678)
1. Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms.
Diebold AE; Boudreaux JP; Wang YZ; Anthony LB; Uhlhorn AP; Ryan P; Mamikunian P; Mamikunian G; Woltering EA
Surgery; 2012 Dec; 152(6):1172-6. PubMed ID: 23102678
[TBL] [Abstract][Full Text] [Related]
2. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel.
Woltering EA; Voros BA; Thiagarajan R; Beyer DT; Ramirez RA; Wang YZ; Mamikunian G; Boudreaux JP
Pancreas; 2018 Aug; 47(7):843-848. PubMed ID: 29939909
[TBL] [Abstract][Full Text] [Related]
3. Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis.
Ardill JE; McCance DR; Stronge WV; Johnston BT
Ann Clin Biochem; 2016 Mar; 53(Pt 2):259-64. PubMed ID: 26038607
[TBL] [Abstract][Full Text] [Related]
4. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract][Full Text] [Related]
5. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
Pavel ME; Hassler G; Baum U; Hahn EG; Lohmann T; Schuppan D
Clin Endocrinol (Oxf); 2005 Apr; 62(4):434-43. PubMed ID: 15807874
[TBL] [Abstract][Full Text] [Related]
7. Validation of neurokinin a assays in the United States and Europe.
Mamikunian P; Ardill JE; O'Dorisio TM; Krutzik SR; Vinik AI; Go VL; Armstrong L; Mamikunian G; Woltering EA
Pancreas; 2011 Oct; 40(7):1000-5. PubMed ID: 21926539
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
9. Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.
Ardill JE; Johnston BT; McCance DR; Eatock M
Ann Clin Biochem; 2017 Mar; 54(2):297-301. PubMed ID: 27638929
[TBL] [Abstract][Full Text] [Related]
10. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
[TBL] [Abstract][Full Text] [Related]
11. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
[TBL] [Abstract][Full Text] [Related]
12. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
[TBL] [Abstract][Full Text] [Related]
13. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
14. Small intestinal neuroendocrine tumors: prognostic factors and survival.
Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
[TBL] [Abstract][Full Text] [Related]
15. Cocoon formation in patients with midgut neuroendocrine tumors: a rare and unrecognized final pathway.
Wang YZ; King H; Diebold A
Pancreas; 2013 Aug; 42(6):944-8. PubMed ID: 23587852
[TBL] [Abstract][Full Text] [Related]
16. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis.
Srirajaskanthan R; Dancey G; Hackshaw A; Luong T; Caplin ME; Meyer T
Endocr Relat Cancer; 2009 Sep; 16(3):967-76. PubMed ID: 19502452
[TBL] [Abstract][Full Text] [Related]
17. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
[TBL] [Abstract][Full Text] [Related]
18. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study.
Taghipour Zahir S; Heidarymeybodi Z; AleSaeidi S
Int J Surg Oncol; 2019; 2019():2912361. PubMed ID: 31186956
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort.
Bösch F; Bruewer K; D'Anastasi M; Ilhan H; Knoesel T; Pratschke S; Thomas M; Rentsch M; Guba M; Werner J; Angele MK
Surgery; 2018 Nov; 164(5):1093-1099. PubMed ID: 30076029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
